UBS’s PLx Pharma Inc. Common Stock PLXP Stock Holding History

UBS’s Portfolio PLXP Stock Details PLXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$5K	Hold	63	–	–	﹤0.01%	9507
2014 Q2	$5K	Buy	+63	New	+$4.9K	﹤0.01%	9550

Other funds holding PLXP

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

PRCM

Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return

TCM

Timpani Capital Management Milwaukee, Wisconsin $209M AUM 62.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS's PLXP Position: Q3 2014 in Review

UBS held its PLx Pharma Inc. Common Stock (PLXP) position steady in Q3 2014 at 63 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #9507.

UBS first reported a position in PLXP in Q2 2014 and has held it in 2 quarters since. 14 funds tracked by Wall St. Rank hold PLXP as of Q3 2014.

UBS held 63 shares of PLx Pharma Inc. Common Stock worth $5K as of Q3 2014.
UBS left its PLx Pharma Inc. Common Stock share count unchanged in Q3 2014.
PLx Pharma Inc. Common Stock made up ﹤0.01% of UBS's portfolio in Q3 2014, its #9507 holding.
UBS first reported a position in PLx Pharma Inc. Common Stock in Q2 2014 and has held it in 2 quarters since.
14 funds tracked by Wall St. Rank held PLx Pharma Inc. Common Stock as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.